A Prospective, Multicenter Post-Market Clinical Follow-up Study to Evaluate the Safety and Performance of the Journey™ II UNI Unicompartmental Knee System
A Prospective, Multicenter Post-Market Clinical Follow-up Study to Evaluate the Safety and Performance of the Journey™ II UNI Unicompartmental Knee System
This clinical study will evaluate the early to midterm safety and performance of the JOURNEY™ II UNI UKS in patients with non-inflammatory degenerative joint disease of the knee requiring lateral or medial knee compartment replacement. Clinical, radiographic, health economic and safety outcomes will be evaluated.
To assess the safety and performance of the JOURNEY™ II UNI UKS in patients with unicompartmental degeneration of the knee by demonstrating non-inferiority of the cumulative percent implant survival in subjects with the JOURNEY™ II UNI UKS implanted, compared to a literature reference rate of 91.7% (AOA annual report 2015)12 at 5 years.
Inclusion Criteria:
Subjects must meet all of the following criteria for inclusion in the study.
Unicompartmental, NIDJD, including OA, traumatic arthritis, or avascular necrosis.
Eighteen (18) years of age or older at the time of surgery.
Skeletally mature in the judgement of the PI.
Has met an acceptable preoperative medical clearance and is free of (or acceptably managed) cardiac, pulmonary, hematological, infection, or other conditions that would pose an excessive operative risk.
Willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires.
Consented to participate in the study by signing the EC-approved ICF.
Exclusion Criteria:
Subjects meeting any of the following criteria must be excluded from participation in the study.